vs

Side-by-side financial comparison of AVALON HOLDINGS CORP (AWX) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

AVALON HOLDINGS CORP is the larger business by last-quarter revenue ($21.5M vs $12.5M, roughly 1.7× Avidity Biosciences, Inc.). AVALON HOLDINGS CORP runs the higher net margin — -1.7% vs -1398.3%, a 1396.7% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 21.7%). AVALON HOLDINGS CORP produced more free cash flow last quarter ($-166.0K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 6.7%).

Avalon Hill Games Inc. is a game company that publishes wargames and strategic board games. It has also published miniature wargaming rules, role-playing games and sports simulations. It is a subsidiary of Hasbro, and operates under the company's "Hasbro Gaming" division.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

AWX vs RNA — Head-to-Head

Bigger by revenue
AWX
AWX
1.7× larger
AWX
$21.5M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+412.3% gap
RNA
434.0%
21.7%
AWX
Higher net margin
AWX
AWX
1396.7% more per $
AWX
-1.7%
-1398.3%
RNA
More free cash flow
AWX
AWX
$156.7M more FCF
AWX
$-166.0K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
6.7%
AWX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AWX
AWX
RNA
RNA
Revenue
$21.5M
$12.5M
Net Profit
$-356.0K
$-174.4M
Gross Margin
17.1%
Operating Margin
0.4%
-1513.5%
Net Margin
-1.7%
-1398.3%
Revenue YoY
21.7%
434.0%
Net Profit YoY
28.4%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AWX
AWX
RNA
RNA
Q4 25
$21.5M
Q3 25
$25.7M
$12.5M
Q2 25
$20.3M
$3.8M
Q1 25
$16.1M
$1.6M
Q4 24
$17.6M
$3.0M
Q3 24
$24.2M
$2.3M
Q2 24
$23.1M
$2.0M
Q1 24
$18.9M
$3.5M
Net Profit
AWX
AWX
RNA
RNA
Q4 25
$-356.0K
Q3 25
$1.9M
$-174.4M
Q2 25
$274.0K
$-157.3M
Q1 25
$-1.5M
$-115.8M
Q4 24
$-497.0K
$-102.3M
Q3 24
$1.8M
$-80.4M
Q2 24
$954.0K
$-70.8M
Q1 24
$-979.0K
$-68.9M
Gross Margin
AWX
AWX
RNA
RNA
Q4 25
17.1%
Q3 25
23.7%
Q2 25
20.6%
Q1 25
14.8%
Q4 24
17.5%
Q3 24
24.6%
Q2 24
22.1%
Q1 24
16.2%
Operating Margin
AWX
AWX
RNA
RNA
Q4 25
0.4%
Q3 25
9.1%
-1513.5%
Q2 25
3.7%
-4448.7%
Q1 25
-7.2%
-8360.9%
Q4 24
-0.8%
-4069.6%
Q3 24
9.4%
-4200.9%
Q2 24
6.3%
-4040.4%
Q1 24
-2.7%
-2178.6%
Net Margin
AWX
AWX
RNA
RNA
Q4 25
-1.7%
Q3 25
7.4%
-1398.3%
Q2 25
1.4%
-4089.3%
Q1 25
-9.3%
-7360.0%
Q4 24
-2.8%
-3439.5%
Q3 24
7.6%
-3441.7%
Q2 24
4.1%
-3461.8%
Q1 24
-5.2%
-1943.4%
EPS (diluted)
AWX
AWX
RNA
RNA
Q4 25
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AWX
AWX
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$4.1M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$38.4M
$1.9B
Total Assets
$87.4M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AWX
AWX
RNA
RNA
Q4 25
$4.1M
Q3 25
$4.6M
$350.2M
Q2 25
$3.7M
$243.9M
Q1 25
$1.3M
$254.2M
Q4 24
$2.8M
$219.9M
Q3 24
$3.9M
$370.2M
Q2 24
$3.8M
$575.8M
Q1 24
$1.2M
$471.4M
Stockholders' Equity
AWX
AWX
RNA
RNA
Q4 25
$38.4M
Q3 25
$38.7M
$1.9B
Q2 25
$36.8M
$1.2B
Q1 25
$36.5M
$1.3B
Q4 24
$38.0M
$1.4B
Q3 24
$38.5M
$1.5B
Q2 24
$36.7M
$1.2B
Q1 24
$35.7M
$830.9M
Total Assets
AWX
AWX
RNA
RNA
Q4 25
$87.4M
Q3 25
$90.7M
$2.1B
Q2 25
$88.1M
$1.4B
Q1 25
$87.6M
$1.5B
Q4 24
$86.2M
$1.6B
Q3 24
$89.1M
$1.6B
Q2 24
$91.7M
$1.3B
Q1 24
$90.6M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AWX
AWX
RNA
RNA
Operating Cash FlowLast quarter
$278.0K
$-156.2M
Free Cash FlowOCF − Capex
$-166.0K
$-156.9M
FCF MarginFCF / Revenue
-0.8%
-1257.6%
Capex IntensityCapex / Revenue
2.1%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$2.1M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AWX
AWX
RNA
RNA
Q4 25
$278.0K
Q3 25
$1.5M
$-156.2M
Q2 25
$3.0M
$-199.7M
Q1 25
$-982.0K
$-124.8M
Q4 24
$-579.0K
$-99.9M
Q3 24
$342.0K
$-65.6M
Q2 24
$3.2M
$-65.0M
Q1 24
$411.0K
$-70.4M
Free Cash Flow
AWX
AWX
RNA
RNA
Q4 25
$-166.0K
Q3 25
$852.0K
$-156.9M
Q2 25
$2.7M
$-203.0M
Q1 25
$-1.4M
$-128.6M
Q4 24
$-1.1M
$-103.8M
Q3 24
$-660.0K
$-67.3M
Q2 24
$2.9M
$-65.5M
Q1 24
$56.0K
$-71.3M
FCF Margin
AWX
AWX
RNA
RNA
Q4 25
-0.8%
Q3 25
3.3%
-1257.6%
Q2 25
13.5%
-5277.1%
Q1 25
-8.5%
-8174.3%
Q4 24
-6.4%
-3491.0%
Q3 24
-2.7%
-2881.8%
Q2 24
12.4%
-3204.6%
Q1 24
0.3%
-2012.3%
Capex Intensity
AWX
AWX
RNA
RNA
Q4 25
2.1%
Q3 25
2.3%
5.7%
Q2 25
1.4%
86.9%
Q1 25
2.4%
238.6%
Q4 24
3.1%
131.7%
Q3 24
4.1%
72.9%
Q2 24
1.5%
26.0%
Q1 24
1.9%
25.8%
Cash Conversion
AWX
AWX
RNA
RNA
Q4 25
Q3 25
0.76×
Q2 25
11.07×
Q1 25
Q4 24
Q3 24
0.19×
Q2 24
3.35×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons